CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug: FDA Warning Letter to Silgan Dispensing Systems, 2026-10-05
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug
TL;DR
Here's the summary: The FDA Center for Drug Evaluation and Research issued a warning letter on October 5, 2026, to Silgan Dispensing Systems (President Earl Lawson) regarding significant Current Good Manufacturing Practice violations at its Spokane, Washington facility (FEI 3011913386) identified during an inspection from March 26-April 2, 2026. The violations include: failure to properly investigate out-of-specification microbiological results for components by invalidating results through averaging rather than appropriate investigation; manufacture and distribution of drug products using contaminated components that subsequently triggered a Class I recall by a customer due to potential fungal contamination; and inadequate corrective actions including incomplete validation and lack of yeast/mold testing in environmental monitoring. The letter also states that certain products labeled on the company's website are unapproved new drugs under section 505(a) of the FD&C Act, making their introduction into interstate commerce prohibited.
Argus analysis
# FDA Warning Letter Analysis: Silgan Dispensing Systems
**Company and Violations**
Silgan Dispensing Systems, a contract manufacturer of over-the-counter drug products based in Richmond, Virginia, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on October 5, 2026, following an inspection of its Spokane, Washington facility (Silgan Unicep Packaging, LLC) conducted March 26–April 2, 2026. The FDA documented significant current good manufacturing practice (CGMP) violations in finished pharmaceuticals manufacturing, resulting in adulterated drug products. Additionally, the agency identified unapproved new drugs based on labeling and website review in July 2026.
**Regulatory Citations and Implications**
The violations center on 21 CFR 211.192, which requires thorough investigation of out-of-specification (OOS) test results and batch failures. Silgan improperly invalidated microbiological testing failures by averaging results—a practice obscuring contamination detection. Components with yeast and mold counts exceeding specifications were released and used in products ultimately subject to a Class I recall due to fungal contamination. The firm lacked cleaning validation procedures, adequate environmental monitoring for mold, and proper change control documentation. These deficiencies violate foundational CGMP requirements designed to ensure manufactured drugs meet safety and quality standards.
**Response Timeline and Industry Monitoring**
Silgan submitted an initial response to FDA Form 483 observations on April 22, 2026, which the agency found inadequate. The warning letter demands comprehensive corrective actions: retrospective review of all invalidated OOS results for US products currently distributed, remediation of investigation systems, and independent assessment of deviation-handling procedures. Compliance officers in contract manufacturing should monitor whether Silgan implements these requirements and whether additional regulatory action—seizure or injunction—follows. Similar operations should evaluate their own microbiological testing protocols and investigation rigor.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Silgan Dispensing Systems MARCS-CMS 734538 — October 05, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Earl Lawson Recipient Title President Silgan Dispensing Systems 1001 Haxall Point, Suite 701 Richmond , VA 23219 United States (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 5, 2026 WARNING LETTER Reference number: 320-27-04 To Mr. Earl Lawson: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products, processes, facility and records. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in legal action without further notice including, without limitation, seizure and injunction. FDA Inspection and Review Violations were observed and documented during an inspection of your drug manufacturing facility, Silgan Unicep Packaging, LLC, Facility Establishment Identifier (FEI) 3011913386, at 4122 South Grove Road, Spokane, Washington, from March 26 to April 2, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). In addition, violations were identified and documented during a review of the product labeling, including the product website at the internet address (b)(4) website in July 2026. Based on our review, “ (b)(4) ” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). We reviewed your April 22, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act Th…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Silgan Dispensing Systems?
- FDA issued the letter (MARCS-CMS 734538) on 2026-10-05 and posted it publicly on fda.gov on 2026-10-13.
- Is the FDA warning letter to Silgan Dispensing Systems publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug: FDA Warning Letter to Silgan Dispensing Systems, 2026-10-05. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-silgan-dispensing-systems-2026-10-05-cgmp
"CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug: FDA Warning Letter to Silgan Dispensing Systems, 2026-10-05." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-silgan-dispensing-systems-2026-10-05-cgmp.
Argus HQ Research. "CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug: FDA Warning Letter to Silgan Dispensing Systems, 2026-10-05." Digital Empire Holdings LLC. Accessed October 14, 2026. https://argushq.ai/fda/warning-letter/fda-wl-silgan-dispensing-systems-2026-10-05-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_silgan_dispensing_systems_2026_10_05_cgmp_2026,
title = {CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug: FDA Warning Letter to Silgan Dispensing Systems, 2026-10-05},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-silgan-dispensing-systems-2026-10-05-cgmp},
note = {Accessed: October 14, 2026}
}